DelfaGLP-1 Atlas

Lead sponsor

AbbVie

4 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

4

Trials led

3

Active

168

Total enrollment

3

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
4

Trials by status

Recruiting
2
Active, not recruiting
1
Completed
1

Trials led

A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295BMI 22-32Ph 1Completed76
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityBMI 30-45Ph 1Recruiting48
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.BMI 23-35Ph 1Recruiting24
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral ContraceptivesBMI 25-35Ph 1Active, not recruiting20